- Home
- Applications
- europe
- patient blood
Refine by
Patient Blood Product Applications Available In Europe
7 applications found
We adapted an autologous ex-vivo gene therapy method to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence. By re-introducing gene-modified HSPCs into the patient, we seek to take advantage of the self-renewing and multi-differentiation capability of HSPCs to enable durable and potentially long-term effects following a single ...
ByGenenta Science based in Milano, ITALY
In the Primary Care segment, blood and urine tests drive nearly 70% of Physician decisions, guiding nearly two-thirds of healthcare ...
ByAtiva Medical based in Shoreview, MINNESOTA (USA)
The treatment differs according to the severity of the haemophilia, which is classified as mild, moderate or severe, depending on how much clotting factor is still detectable in the patient’s blood. Most patients have severe haemophilia A (residual activity of factor VIII less than ...
ByBiotest AG based in Dreieich, GERMANY
You need a complete answer to provide the best ...
ByBiocept based in San Diego, CALIFORNIA (USA)
The classical (but rarely observed) malaria attack lasts 6–10 ...
ByAmivas (US), LLC based in Frederick, MARYLAND (USA)
Standard treatment for advanced colorectal cancer generally involves surgical resection and chemotherapy. However, the recent emergence of targeted therapies, particularly those that inhibit EGFR, has provided treatment options that extend survival for a subset of patients. Unfortunately, this benefit does not extend to patients whose tumors contain mutations in EGFR signaling components KRAS and BRAF, which together represent 50% of all colorectal cancers. This makes characterizing these molecular markers an ...
ByBiocept based in San Diego, CALIFORNIA (USA)
A liquid biopsy from Biocept gives you a new tool for profiling breast cancer—with a simple blood ...
ByBiocept based in San Diego, CALIFORNIA (USA)